{{Drugbox
| Watchedfields = changed
| verifiedrevid = 447991507
| IUPAC_name = (-)-17-(Cyclopropylmethyl)-morphinan-3,14-diol
| image = Oxilorphan.svg
| width = 140

<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 42281-59-4
| ATC_prefix = None
| ATC_suffix =  
| PubChem = 5361090
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 16736680
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 9Y9J2J74TO
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D05299

<!--Chemical data-->
| C=20 | H=27 | N=1 | O=2 
| molecular_weight = 313.44 g/mol
| smiles = Oc3ccc4C[C@H]1N(CC[C@@]2(CCCC[C@@]12O)c4c3)CC5CC5
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C20H27NO2/c22-16-6-5-15-11-18-20(23)8-2-1-7-19(20,17(15)12-16)9-10-21(18)13-14-3-4-14/h5-6,12,14,18,22-23H,1-4,7-11,13H2/t18-,19+,20-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = STBZIDOIKQNFCQ-HSALFYBXSA-N
| synonyms =  
}}

'''Oxilorphan''' ([[International Nonproprietary Name|INN]], [[United States Adopted Name|USAN]]) (developmental code name '''<small>L</small>-BC-2605''') is an [[opioid antagonist]] of the [[morphinan]] family that was never marketed.<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA916|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=916–}}</ref> It acts as a [[mu opioid receptor|μ-opioid receptor]] (MOR) [[receptor antagonist|antagonist]] but a [[kappa opioid receptor|κ-opioid receptor]] (KOR) [[partial agonist]], and has similar effects to [[naloxone]] and around the same potency as an MOR antagonist.<ref>Pircio AW, Gylys JA. Oxilorphan (l-N-cyclopropylmethyl-3,14-dihydroxymorphinan): a new synthetic narcotic antagonist. ''Journal of Pharmacology and Experimental Therapeutics''. 1975 Apr;193(1):23-34.</ref> Oxilorphan has some weak [[partial agonist]] actions at the MOR (with [[miosis]], [[nausea]], [[dizziness]], and some [[euphoria]] observed)<ref>Sellers EM, Thakur R. Partial agonist properties and toxicity of oral oxilorphan. ''Journal of Clinical Pharmacology''. 1976 Apr;16(4):183-7.</ref><ref name="AcademicPress1974">{{cite book|title=ANNUAL REPORTS IN MED CHEMISTRY V9 PPR|url=https://books.google.com/books?id=rZBH1_7Tx6UC&pg=PA41|date=22 November 1974|publisher=Academic Press|isbn=978-0-08-058353-2|pages=41–}}</ref> and can produce [[hallucinogen]]ic/[[dissociative]] effects at sufficient doses, indicative of KOR activation.<ref>Leander JD. Evidence that nalorphine, butorphanol and oxilorphan are partial agonists at a kappa-opioid receptor. ''European Journal of Pharmacology''. 1983 Jan 21;86(3-4):467-70.</ref> It was trialed for the treatment of [[opioid addiction]], but was not developed commercially.<ref>Tennant FS Jr, Tate JA, Ruckel E. Clinical trial in post-addicts with oxilorphan (levo-BC-2605): a new narcotic antagonist. ''Drug and Alcohol Dependence''. 1976 Jun;1(5):329-37.</ref> The KOR agonist effects of oxilorphan are associated with [[dysphoria]], which combined with its hallucinogenic effects, serve to limit its clinical usefulness; indeed, many patients who experienced these side effects refused to take additional doses in clinical trials.<ref name="Dependence1975">{{cite book|author=National Research Council (U.S.). Committee on Problems of Drug Dependence|title=Problems of drug dependence|url=https://books.google.com/books?id=3aEeAQAAMAAJ|year=1975|publisher=National Academy of Sciences.}}</ref>

==See also==
* [[Butorphanol]]
* [[Cyclorphan]]
* [[Ketorfanol]]
* [[Levallorphan]]
* [[Levomethorphan]]
* [[Levorphanol]]
* [[Nalbuphine]]
* [[Proxorphan]]
* [[Xorphanol]]

==References==
{{Reflist|2}}


{{Hallucinogens}}
{{Opioidergics}}

[[Category:Analgesics]]
[[Category:Dissociative drugs]]
[[Category:Morphinans]]
[[Category:Opioid antagonists]]
[[Category:Antidotes]]
[[Category:Phenols]]
[[Category:Alcohols]]
[[Category:Kappa agonists]]
[[Category:Synthetic opioids]]


{{nervous-system-drug-stub}}